cabozantinib

Good for Bladder Cancer, Better for Kidney Cancer Bookmark

This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

.

Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers Bookmark

Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In recent clinical trials, the drug cabozantinib is being found to greatly increase progression-free survival.

Go to full article published by Targeted Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.